<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011058</url>
  </required_header>
  <id_info>
    <org_study_id>VT3996-202</org_study_id>
    <nct_id>NCT05011058</nct_id>
  </id_info>
  <brief_title>An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</brief_title>
  <acronym>NAVAL-1</acronym>
  <official_title>An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viracta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viracta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir&#xD;
      in patients with relapsed/refractory EBV-positive lymphomas&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with EBV-associated lymphomas have inferior outcomes with standard-of-care therapies&#xD;
      compared to those with EBV-negative disease. Nanatinostat is a selective class I HDAC&#xD;
      inhibitor which induces EBV lytic phase protein generation, activating (val)ganciclovir to&#xD;
      its cytotoxic form. This open-label, multicenter, multinational, single-arm, basket study&#xD;
      employs a Simon's 2-stage design to allow termination of enrollment into cohorts where&#xD;
      treatment appears futile, and will include the following cohorts of patients with EBV+&#xD;
      relapsed/refractory lymphomas:&#xD;
&#xD;
      This is an open-label, multicenter, multinational single-arm, Phase 2 basket design study,&#xD;
      utilizing Simon's 2-stage design. The study will include 7 cohorts of patients with the&#xD;
      following EBV+ relapsed/refractory lymphomas:&#xD;
&#xD;
        1. EBV+ diffuse large B-cell lymphoma (DLBCL, NOS)&#xD;
&#xD;
        2. Extranodal NK/T-cell lymphoma (ENKTL)&#xD;
&#xD;
        3. Peripheral T-cell lymphoma (PTCL), including PTCL-NOS and AITL&#xD;
&#xD;
        4. Hodgkin lymphoma (HL)&#xD;
&#xD;
        5. Post-transplant lymphoproliferative disorder (PTLD)&#xD;
&#xD;
        6. HIV-associated lymphomas (Plasmablastic, Burkitt, Hodgkin, DLBCL)&#xD;
&#xD;
        7. EBV+ lymphoproliferative disorders other than the above&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, single-arm study utilizing a basket trial design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approxiately 3 years</time_frame>
    <description>Assessed by an Independent Review Committee (IRC) per the 2007 International Working Group Response Criteria (IWGRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approxiately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next anti-lymphoma treatment (TTNLT)</measure>
    <time_frame>Approxiately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approxiately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Approxiately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approxiately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>Approxiately 28 days following the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter - time to maximum plasma concentration [tmax],</measure>
    <time_frame>Approxiately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter - maximum plasma concentration [Cmax]</measure>
    <time_frame>Approxiately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]</measure>
    <time_frame>Approxiately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Epstein-Barr Virus Associated Lymphoproliferative Disorder</condition>
  <condition>EBV-Related PTLD</condition>
  <condition>EBV Related Non-Hodgkin's Lymphoma</condition>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <condition>EBV-Positive DLBCL, Nos</condition>
  <condition>EBV Associated Lymphoma</condition>
  <condition>EBV-Related Hodgkin Lymphoma</condition>
  <condition>EBV Related PTCL, Nos</condition>
  <arm_group>
    <arm_group_label>Nanatinostat with Valganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.&#xD;
Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanatinostat in combination with valganciclovir</intervention_name>
    <description>Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles&#xD;
Other name: VRx-3996&#xD;
Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles</description>
    <arm_group_label>Nanatinostat with Valganciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies&#xD;
&#xD;
          -  EBV+ DLBCL, NOS: Must have received at least one course of an anti-CD20 immunotherapy,&#xD;
             and at least one course of anthracycline-based chemotherapy&#xD;
&#xD;
          -  PTLD: Must have received immunotherapy with an anti-CD20 agent.&#xD;
&#xD;
          -  Hodgkin lymphoma: Must have received at least one course of anthracycline-based&#xD;
             chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be&#xD;
             ineligible for an anti-PD-1 agent and CD30-directed therapy.&#xD;
&#xD;
          -  For extranodal NK/T-cell lymphoma patients only: Relapsed/refractory disease following&#xD;
             1 or more prior systemic therapies. Patients must have failed an&#xD;
             asparaginase-containing regimen.&#xD;
&#xD;
          -  No available therapies in the opinion of the Investigator&#xD;
&#xD;
          -  Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell&#xD;
             transplantation or CAR-T therapy&#xD;
&#xD;
          -  Measurable disease per Lugano 2007&#xD;
&#xD;
          -  ECOG performance status 0, 1, 2&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of CNS involvement by lymphoma&#xD;
&#xD;
          -  Systemic anticancer therapy or CAR-T within 21 days&#xD;
&#xD;
          -  Antibody (anticancer) agents within 28 days&#xD;
&#xD;
          -  Less than 60 days from prior autologous hematopoietic stem cell or solid organ&#xD;
             transplant&#xD;
&#xD;
          -  Less than 90 days from prior allogeneic transplant.&#xD;
&#xD;
          -  Daily corticosteroids (â‰¥20 mg of prednisone or equivalent) within week prior to Cycle&#xD;
             1 Day 1&#xD;
&#xD;
          -  Inability to take oral medication, malabsorption syndrome or any other&#xD;
             gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption&#xD;
             of nanatinostat and valganciclovir.&#xD;
&#xD;
          -  Active infection requiring systemic therapy (excluding viral upper respiratory tract&#xD;
             infections).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Rojkjaer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Viracta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert McRae</last_name>
    <phone>858-400-8470</phone>
    <email>ClinicalTrials@Viracta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Hematology and Blood and Marrow Transplant</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Florida Hematology and Oncology Center</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center - Jefferson Health</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Maisonneuve-Rosemont</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux Cedex</city>
        <state>Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Universitaire PitiÃ© SalpÃªtriÃ¨re</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Limoges</name>
      <address>
        <city>Limoges cedex</city>
        <state>Limousin</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Haut-LÃ©vÃªque</name>
      <address>
        <city>Pessac</city>
        <state>Nouvelle-Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier DÃ©partemental VendÃ©e</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <state>Pays De La Loire</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint-Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <state>Provence Alpes Cote d'Azur</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <state>Rhone-Alps</state>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <state>Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbugdo</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ClinicalTrials@Viracta.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EBV positive post-transplant lymphoproliferative disorder (PTLD)</keyword>
  <keyword>EBV lymphoma</keyword>
  <keyword>HIV-associated lymphoma</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>EBV positive T cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

